• 1
    Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S5S.
  • 2
    Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 514.
  • 3
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 55662.
  • 4
    McQuillan GM, Alter MJ, Moyer LA, et al. A population-based serologic study of hepatitis C virus infection in the United States. In: RizettoM, PurcellRH, GerinJL, VerneG, eds. Viral Hepatitis and Liver Disease. Turin: Edizioni Minerva Medica, 1997: 26770.
  • 5
    Hoofnagle JH. Chronic Viral Hepatitis C — Clinical. Postgraduate Course. Chicago: Association for the Study of Liver Diseases, 1998.
  • 6
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 4152.
  • 7
    Fried MW, Shiffman M, Reddy KR, et al. Pegylated (40 kDa) interferon alpha-2a in combination with ribavirin: efficacy and safety results from a phase III randomized, controlled, actively controlled, multicenter study. Gastroenterology 2001; 120: A55.
  • 8
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis [see comments]. Hepatology 1998; 27: 20912.
  • 9
    Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41: 37784.
  • 10
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 148592.
  • 11
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 12
    Kraus M, Schaefer A, Csef H, Faller H, Mörk H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C. Associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 2001; 46: 20605.
  • 13
    Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 5102.
  • 14
    Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173: 35961.
  • 15
    Schäfer M, Schmidt F, Amann B, Schlosser S, Loeschke K, Grunze H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42: 435.
  • 16
    Goldman LS. Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35: 4123.
  • 17
    Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000; 41: 43941.
  • 18
    McAllister-Williams RH, Young AH, Menkes DB. Antidepressant response reversed by interferon. Br J Psychiatr 2000; 176: 93.
  • 19
    Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 9616.
  • 20
    Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV), 4th edn. Washington DC: American Psychiatric Association, 1994.
  • 21
    Margraf J, Schneider S, Ehlers A. Diagnostisches Interview bei Psychischen Störungen (German modified version of ADIS-R Anxiety Disorders Interview Schedule-Revised; DiNardo PA, Barlow DH, 1988). Berlin: Springer, 1994.
  • 22
    Herrmann C, Buss U, Snaith RP. HADS-D. Hospital Anxiety and Depression Scale — Deutsche Version. Ein Fragebogen zur Erfassung von Angst und Depressivität in der somatischen Medizin. Bern: Huber, 1995.
  • 23
    Franke GH. SCL-90-R Symptom-Checkliste von Derogatis — Deutsche Version (Testmappe mit Handanweisung, 5 Frageboegen, 5 Auswertungsboegen und 5 Boegen Graphisches Auswertungsschema). Symptom Checklist 90 Items Revised (Derogatis LR, 1977)— German version/author. Weinheim: Beltz, 1995.
  • 24
    SPSS. SPSS für Windows 10.0.7. Chicago: SPSS Inc., 2000.
  • 25
    Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997; 42: 18691.
  • 26
    Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88: 7601.
  • 27
    Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349: 31724.
  • 28
    Abe S, Hori T, Suzuki T, Baba A, Shiraishi H, Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 1999; 24: 35963.
  • 29
    Licinio J, Kling MA, Hauser P. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 1998; 25: 308.
  • 30
    Yokoyama A, Kimura Y, Shigemura J. Psychiatric side effects of interferon. J Toxicol Sci 1996; 21: 936.
  • 31
    Mongeau R, Blier P, De Montigny C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Brain Res Rev 1997; 23: 14595.
  • 32
    Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatr 1996; 53: 77784.
  • 33
    Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55: 85120.
  • 34
    Baldwin DS, Hawley CJ, Mellors K. A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. J Pharmacol 2001; 15: 1615.
  • 35
    Helmchen C, Boerner RJ, Meyendorf R, Hegerl U. Reversible hepatotoxicity of paroxetine in a patient with major depression. Pharmacopsychiatry 1996; 29: 2236.
  • 36
    Nemeroff CB. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 1993; 13: 10S7S.
  • 37
    Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001; 16: 16978.
  • 38
    Aberg-Wistedt A, Agren H, Ekselius L, Bengtson F, Akerblad AC. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000; 20: 64552.DOI: 10.1097/00004714-200012000-00010
  • 39
    Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatr 1998; 10: 14550.
  • 40
    Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatr 1996; 57: 4652.
  • 41
    Stain-Malmgren R, Khoury AE, Aberg-Wistedt A, Tham A. Serotonergic function in major depression and effect of sertraline and paroxetine treatment. Int Clin Psychopharmacol 2001; 16: 93101.
  • 42
    Maes M, Song C, Lin AH, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 3709.